Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 1.00 |
| ▸ | TOP2A | P11388 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | NT5E | P21589 | 2/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | CES2 | O00748 | 2/20 | 0.74 |
| ▸ | CES1 | P23141 | 2/20 | 0.74 |
| ▸ | RORC | P51449 | 4/20 | 0.70 |
| ▸ | ALB | P02768 | 3/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | GLI1 | P08151 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.70 |
| ▸ | DPP4 | P27487 | 1/20 | 0.70 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.70 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.70 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.70 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betulin SCHEMBL19452465 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL13908773 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL8656184 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL13806589 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL7749571 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL7215658 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL15074885 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL9905923 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL20776118 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL8223535 | 1.00 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088757-B2 | Betulinol derivatives as anti-cancer agents | BIORINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8008280-B2 | Betulinol derivatives as anti-HIV agents | BIORINGS LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008280-B2 | Betulinol derivatives as anti-HIV agents | BIORINGS LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | SAXENA RESEARCH, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | SAXENA RESEARCH, LLC | 2008-11-20 | — | — | US | disclosed |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | SAXENA RESEARCH, LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | BET1, BRDT, BRCA1 | PTPN1 4631/4885TOP2A 191/4885USP2 4167/4885 |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | BET1, NFATC1, CD4 | PTPN1 1987/4885TOP2A 2384/4885USP2 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.